News & Updates

Some patients with heart failure with reduced ejection fraction (HFrEF) need a loop diuretic dose reduction within 2‒3 months following initiation of sacubitril-valsartan, suggests a study.

The addition of salt to foods appears to increase the risk of cardiovascular diseases (CVDs), particularly heart failure and ischaemic heart disease (IHD), suggests a study.

Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.

Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.

In patients with type 2 diabetes (T2D), maximum home blood pressure (BP) may be used as a potential marker of subsequent cardiovascular events, suggests a retrospective cohort study.

In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.

Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.

Isometric exercise training (IET) appears to be a good long-term intervention in managing resting blood pressure (BP), reports a recent study. IET delivers clinically important, chronic BP adaptations in patients at risk of hypertension.